COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?

Descripción del Articulo

 Viral infection with the SARS-CoV-2 coronavirus produces a disease called COVID–19, characterized by a severe acute respiratory syndrome that can progress to multiple organ failure and death. Patients who have this entity commonly present various comorbidities, among which chronic kidney d...

Descripción completa

Detalles Bibliográficos
Autor: Vizcarra-Vizcarra, Cristhian Adolfo
Formato: artículo
Fecha de Publicación:2020
Institución:Sociedad Peruana de Medicina Interna
Repositorio:Revista SPMI - Revista de la Sociedad Peruana de Medicina Interna
Lenguaje:español
OAI Identifier:oai:ojs.medicinainterna.net.pe:article/563
Enlace del recurso:http://revistamedicinainterna.net/index.php/spmi/article/view/563
Nivel de acceso:acceso abierto
Materia:COVID-19
ACE – 2
Chronic kidney disease
Hemodialysis
ECA-2
enfermedad renal crónica
hemodiálisis
id 1609-7173_5825fc4820e5b8979d0f96af4d15badc
oai_identifier_str oai:ojs.medicinainterna.net.pe:article/563
network_acronym_str 1609-7173
repository_id_str
network_name_str Revista SPMI - Revista de la Sociedad Peruana de Medicina Interna
spelling COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?COVID-19 y enfermedad renal crónica: ¿qué debemos saber sobre la relación ECA/ECA-2?Vizcarra-Vizcarra, Cristhian AdolfoCOVID-19ACE – 2Chronic kidney diseaseHemodialysisCOVID-19ECA-2enfermedad renal crónicahemodiálisis Viral infection with the SARS-CoV-2 coronavirus produces a disease called COVID–19, characterized by a severe acute respiratory syndrome that can progress to multiple organ failure and death. Patients who have this entity commonly present various comorbidities, among which chronic kidney disease stands out, which could be related to severe infection. High levels of ACE / ACE – 2 ratio plays an important role in the pathophysiology of chronic kidney disease and in different cardiovascular diseases, predisposing these patients to develop infection with a poor prognosis. Up to 46% of hemodialysis patients with COVID are asymptomatic, although some present with fever, cough, and dyspnea, and it is common to observe gastrointestinal symptoms that must be taken into account when evaluating this group of patients in dialysis units.La infección viral por el coronavirus SARS-CoV-2 produce una enfermedad denominada COVID–19, caracterizada por un síndrome respiratorioagudo grave que puede progresar a falla multiorgánica y muerte. Los pacientes que cursan con dicha entidad, comúnmente, presentan diversascomorbilidades, entre las que resalta la enfermedad renal crónica, la que podría estar relacionada a infección severa. La relación ECA/ECA-2 elevada, juega un papel importante en la fisiopatología de la enfermedad renal crónica y en diferentes enfermedades cardiovasculares,predisponiendo a estos pacientes a desarrollar la infección con mal pronóstico. Hasta un 46% de los pacientes en hemodiálisis con COVID-19son asintomáticos, aunque algunos cursan con fiebre, tos y disnea, y es común observar síntomas gastrointestinales que deben ser tomadosen cuenta al evaluar a este grupo de pacientes en las unidades de diálisis.Sociedad Peruana de Medicina Interna2020-12-19info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://revistamedicinainterna.net/index.php/spmi/article/view/56310.36393/spmi.v33i4.563Revista de la Sociedad Peruana de Medicina Interna; Vol. 33 Núm. 4 (2020); 155-160Revista de la Sociedad Peruana de Medicina Interna; Vol 33 No 4 (2020); 155-1601609-71731681-972110.36393/spmi.v33i4reponame:Revista SPMI - Revista de la Sociedad Peruana de Medicina Internainstname:Sociedad Peruana de Medicina Internainstacron:SPMIspahttp://revistamedicinainterna.net/index.php/spmi/article/view/563/635Derechos de autor 2020 Cristhian Adolfo Vizcarra-Vizcarrahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccess2021-05-29T16:56:13Zmail@mail.com -
dc.title.none.fl_str_mv COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
COVID-19 y enfermedad renal crónica: ¿qué debemos saber sobre la relación ECA/ECA-2?
title COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
spellingShingle COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
Vizcarra-Vizcarra, Cristhian Adolfo
COVID-19
ACE – 2
Chronic kidney disease
Hemodialysis
COVID-19
ECA-2
enfermedad renal crónica
hemodiálisis
title_short COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
title_full COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
title_fullStr COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
title_full_unstemmed COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
title_sort COVID-19 and chronic kidney disease: what should we know about ACE/ACE-2 ratio?
dc.creator.none.fl_str_mv Vizcarra-Vizcarra, Cristhian Adolfo
author Vizcarra-Vizcarra, Cristhian Adolfo
author_facet Vizcarra-Vizcarra, Cristhian Adolfo
author_role author
dc.subject.none.fl_str_mv COVID-19
ACE – 2
Chronic kidney disease
Hemodialysis
COVID-19
ECA-2
enfermedad renal crónica
hemodiálisis
topic COVID-19
ACE – 2
Chronic kidney disease
Hemodialysis
COVID-19
ECA-2
enfermedad renal crónica
hemodiálisis
dc.description.none.fl_txt_mv  Viral infection with the SARS-CoV-2 coronavirus produces a disease called COVID–19, characterized by a severe acute respiratory syndrome that can progress to multiple organ failure and death. Patients who have this entity commonly present various comorbidities, among which chronic kidney disease stands out, which could be related to severe infection. High levels of ACE / ACE – 2 ratio plays an important role in the pathophysiology of chronic kidney disease and in different cardiovascular diseases, predisposing these patients to develop infection with a poor prognosis. Up to 46% of hemodialysis patients with COVID are asymptomatic, although some present with fever, cough, and dyspnea, and it is common to observe gastrointestinal symptoms that must be taken into account when evaluating this group of patients in dialysis units.
La infección viral por el coronavirus SARS-CoV-2 produce una enfermedad denominada COVID–19, caracterizada por un síndrome respiratorioagudo grave que puede progresar a falla multiorgánica y muerte. Los pacientes que cursan con dicha entidad, comúnmente, presentan diversascomorbilidades, entre las que resalta la enfermedad renal crónica, la que podría estar relacionada a infección severa. La relación ECA/ECA-2 elevada, juega un papel importante en la fisiopatología de la enfermedad renal crónica y en diferentes enfermedades cardiovasculares,predisponiendo a estos pacientes a desarrollar la infección con mal pronóstico. Hasta un 46% de los pacientes en hemodiálisis con COVID-19son asintomáticos, aunque algunos cursan con fiebre, tos y disnea, y es común observar síntomas gastrointestinales que deben ser tomadosen cuenta al evaluar a este grupo de pacientes en las unidades de diálisis.
description  Viral infection with the SARS-CoV-2 coronavirus produces a disease called COVID–19, characterized by a severe acute respiratory syndrome that can progress to multiple organ failure and death. Patients who have this entity commonly present various comorbidities, among which chronic kidney disease stands out, which could be related to severe infection. High levels of ACE / ACE – 2 ratio plays an important role in the pathophysiology of chronic kidney disease and in different cardiovascular diseases, predisposing these patients to develop infection with a poor prognosis. Up to 46% of hemodialysis patients with COVID are asymptomatic, although some present with fever, cough, and dyspnea, and it is common to observe gastrointestinal symptoms that must be taken into account when evaluating this group of patients in dialysis units.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-19
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://revistamedicinainterna.net/index.php/spmi/article/view/563
10.36393/spmi.v33i4.563
url http://revistamedicinainterna.net/index.php/spmi/article/view/563
identifier_str_mv 10.36393/spmi.v33i4.563
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv http://revistamedicinainterna.net/index.php/spmi/article/view/563/635
dc.rights.none.fl_str_mv Derechos de autor 2020 Cristhian Adolfo Vizcarra-Vizcarra
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Derechos de autor 2020 Cristhian Adolfo Vizcarra-Vizcarra
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedad Peruana de Medicina Interna
publisher.none.fl_str_mv Sociedad Peruana de Medicina Interna
dc.source.none.fl_str_mv Revista de la Sociedad Peruana de Medicina Interna; Vol. 33 Núm. 4 (2020); 155-160
Revista de la Sociedad Peruana de Medicina Interna; Vol 33 No 4 (2020); 155-160
1609-7173
1681-9721
10.36393/spmi.v33i4
reponame:Revista SPMI - Revista de la Sociedad Peruana de Medicina Interna
instname:Sociedad Peruana de Medicina Interna
instacron:SPMI
reponame_str Revista SPMI - Revista de la Sociedad Peruana de Medicina Interna
collection Revista SPMI - Revista de la Sociedad Peruana de Medicina Interna
instname_str Sociedad Peruana de Medicina Interna
instacron_str SPMI
institution SPMI
repository.name.fl_str_mv -
repository.mail.fl_str_mv mail@mail.com
_version_ 1701112607117672448
score 13.836569
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).